New anti-inflammatory for post-cataract surgery

摘要

A NEW eye solution is available for the treatment of postoperative ocular inflammation following cataract extraction in adults. Yellox (bromfenac sodium sesquihydrate) is a non-steroidal anti-inflammatory drug and is thought to be effective due to its ability to block prostaglandin synthesis via cyclo-oxygenase 2 inhibition. The clinical safety and efficacy of Yellox was determined in phase III studies where doses were given twice daily, 24 hours after cataract surgery and continued for up to 14 days. Treatment effect was evaluated up to 29 days. The studies showed that a significantly greater proportion of patients in the Yellox group than in the placebo group (P<0.0001) experienced complete clearance of ocular inflammation at day 15 (64.0 per cent vs 43.3 per cent).